Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 235,105,460 papers from all fields of science
Search
Sign In
Create Free Account
SN 38
Known as:
SN-38
, SN38 cpd
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
7-ethyl-10-hydroxycamptothecin
irinotecan
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Abstract 2904: SN-38 antibody-drug conjugates as a novel platform for solid cancer therapy: preclinical science
D. Goldenberg
,
Thomas M Cardillo
,
+4 authors
S. Govindan
2014
Corpus ID: 70481553
SN-38 is the active metabolite of the camptothecin prodrug, CPT-11 (irinotecan), which is a solid cancer therapeutic…
Expand
2013
2013
[Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G].
B. Valenzuela Jiménez
,
M. González Sales
,
+5 authors
J. P. Pérez Ruixo
Farmacia Hospitalaria
2013
Corpus ID: 196419086
OBJECTIVE To evaluate the influence of genetic polymorphism in UGT1A1, UGT1A7 and UGT1A9 on the population pharmacokinetics of…
Expand
2012
2012
Increased expression of drug-metabolizing enzymes in human hepatocarcinoma FLC-4 cells cultured on micro-space cell culture plates.
Kaoru Kobayashi
,
Akane Yoshida
,
+5 authors
K. Chiba
Drug Metabolism and Pharmacokinetics
2012
Corpus ID: 11319226
Human hepatocellular carcinoma cell lines cultured in a monolayer show negligible activities of drug-metabolizing enzymes such as…
Expand
2012
2012
Abstract 2526: Optimal cleavable linker for antibody-SN-38 conjugates for cancer therapy: Impact of linker's stability on efficacy
S. Govindan
,
Thomas M Cardillo
,
Fatma Tat
,
R. Arrojo
,
R. Sharkey
,
D. Goldenberg
2012
Corpus ID: 70859485
We reported therapeutic results of antibody (MAb) conjugates of the topo I inhibitor, SN-38, in human tumor xenografts in nude…
Expand
2009
2009
Abstract #3233: Targeted therapy of human colonic, lung, and pancreatic cancer xenografts, growing in nude mice, with potent antibody conjugates of SN-38
S. Govindan
,
Thomas M Cardillo
,
S. Moon
,
D. Goldenberg
2009
Corpus ID: 196554882
SN-38 is a potent topoisomerase I inhibitor and the active drug form of the clinically used cancer therapeutic, CPT-11. To…
Expand
2008
2008
A genotype-based dose-escalation study of irinotecan in advanced colorectal cancer patients treated in second-line of chemotherapy
E. Marcuello
,
L. Paré
,
+4 authors
M. Baiget
2008
Corpus ID: 73979383
14599 Background: The dose-limiting toxicities of Irinotecan are diarrhea and neutropenia. The risk of developing these…
Expand
2004
2004
Advances in Brief Imatinib Mesylate Is a Potent Inhibitor of the ABCG 2 ( BCRP ) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro
P. Houghton
,
G. Germain
,
+4 authors
P. Traxler
2004
Corpus ID: 21421987
Imatinib mesylate (Gleevec, STI571) is a kinase inhibitor selective for Bcr-Abl, activated c-Kit kinases, and platelet-derived…
Expand
2001
2001
Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction
S. Ong
,
S. Clarke
,
J. Bishop
,
H. Dodds
,
L. Rivory
Anti-Cancer Drugs
2001
Corpus ID: 23559279
Various clinical and laboratory parameters have been investigated for their ability to predict toxicity arising from the use of…
Expand
1999
1999
Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin.
Maja J.A. de Jonge
,
J. Verweij
,
+7 authors
A. Sparreboom
Clinical Cancer Research
1999
Corpus ID: 9255957
In this study, 11 patients with solid tumors were randomized to receive irinotecan (CPT-11; 200 mg/m2) as a 90-min i.v. infusion…
Expand
1995
1995
Advantage of combined treatment of CPT-11 and 5-fluorouracil.
H. Matsuoka
,
K. Yano
,
+4 authors
H. Tomoda
Anticancer Research
1995
Corpus ID: 41211417
The combined chemotherapy of SN-38, active metabolite of CPT-11, and 5-FU in vitro was examined using human cell lines and…
Expand